tbuckley/cabot-search huggingface dataset:
Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues
Authors: Sara Montagnese, Jasmohan S. Bajaj
Journal: Drugs (2019)

Hepatic encephalopathy (HE) has a major impact on health-related quality of life (HRQOL) in patients, which has clinical and psychosocial consequences. HRQOL in cirrhosis has been measured by generic and liver-specific instruments, with most studies indicating a negative impact of HE. HRQOL abnormalities span daily functioning, sleep–wake cycle changes, and the ability to work. Of these, sleep–wake cycle changes have a major effect on HRQOL, which remains challenging to treat. The personal effect of HRQOL is modulated by the presence of HE, the etiology of cirrhosis, and cognitive reserve. Patients with higher cognitive reserve are able to tolerate HE and its impact on HRQOL better than those with a poor cognitive reserve. The impact of HRQOL impairment is felt by patients (higher mortality and poor daily functioning), as well as by caregivers and families. Caregivers of patients with HE bear a major financial and psychological burden, which may affect their personal health and longevity.
Eosinophil-derived IL-13 promotes emphysema
Authors: Alfred D. Doyle, Manali Mukherjee, William E. LeSuer, Tyler B. Bittner, Saif M. Pasha, Justin J. Frere, Joseph L. Neely, Jake A. Kloeber, Kelly P. Shim, Sergei I. Ochkur, Terence Ho, Sarah Svenningsen, Benjamin L. Wright, Matthew A. Rank, James J. Lee, Parameswaran Nair, Elizabeth A. Jacobsen
Journal: European Respiratory Journal (2019)

The inflammatory responses in chronic airway diseases leading to emphysema are not fully defined. We hypothesised that lung eosinophilia contributes to airspace enlargement in a mouse model and to emphysema in patients with chronic obstructive pulmonary disease (COPD).A transgenic mouse model of chronic type 2 pulmonary inflammation (I5/hE2) was used to examine eosinophil-dependent mechanisms leading to airspace enlargement. Human sputum samples were collected for translational studies examining eosinophilia and matrix metalloprotease (MMP)-12 levels in patients with chronic airways disease.Airspace enlargement was identified in I5/hE2 mice and was dependent on eosinophils. Examination of I5/hE2 bronchoalveolar lavage identified elevated MMP-12, a mediator of emphysema. We showed, in vitro, that eosinophil-derived interleukin (IL)-13 promoted alveolar macrophage MMP-12 production. Airspace enlargement in I5/hE2 mice was dependent on MMP-12 and eosinophil-derived IL-4/13. Consistent with this, MMP-12 was elevated in patients with sputum eosinophilia and computed tomography evidence of emphysema, and also negatively correlated with forced expiratory volume in 1 s.A mouse model of chronic type 2 pulmonary inflammation exhibited airspace enlargement dependent on MMP-12 and eosinophil-derived IL-4/13. In chronic airways disease patients, lung eosinophilia was associated with elevated MMP-12 levels, which was a predictor of emphysema. These findings suggest an underappreciated mechanism by which eosinophils contribute to the pathologies associated with asthma and COPD.
Predictors of survival in pancreatic squamous cell carcinoma (PSCC): An analysis from the National Cancer Database (NCDB).
Authors: Anuhya Kommalapati, Sri Harsha Tella, Gaurav Goyal, Amit Mahipal
Journal: Journal of Clinical Oncology (2019)

399 Background: PSCC is a rare form of exocrine pancreatic malignancy with a dismal prognosis. Using the NCDB, we determined the prognostic factors and survival outcomes of PSCC in the United States. Methods: We performed a retrospective analysis of patients with histologically confirmed PSCC from 2004-2015 using NCDB. Kaplan-Meier method and log-rank test were used to perform overall survival (OS) analysis. Hazard Ratios were calculated using the Cox-proportional hazard method. Results: Of the 654 cases included in our analysis, 46% were female. Median age at diagnosis was 70 years and did not differ by sex (p = 0.19). The proportion of patients with stage I, II, III and IV diseases were 5%, 18%, 12%, and 54%, respectively (10%, unknown stage). Among these, 23% (35 of 150) of stage I and II disease, 10% (8 of 78) of stage III, and 2% (7 of 353) received surgical resection of the primary tumor. The rate of R0 resection was 74% in stage I and II; 38% in stage III; 29% in stage IV disease. Median OS for the entire cohort was 4 months and was significantly higher in patients who received surgical resection of the primary tumor (17 vs. 4 months, p &lt; 0.001). On stage wise sub-group analysis, stage I-II patients had OS benefit from surgery (21 vs. 5 months, p &lt; 0.001) as opposed to stage III (7 vs. 6 months, p = 0.31) and IV disease (5 vs. 3 months, p = 0.17). Adjuvant chemotherapy had no role in prolonging survival in stage I-II disease (20 vs 24 months, p = 0.6). Stage IV patients treated with chemotherapy had a better median OS than those without (5 vs. 2 months, p &lt; 0.0001). On Cox multivariable analysis, stage IV disease (HR: 1.92 CI: 1.46-2.52, p &lt; 0.001) and advanced patient age (HR: 1.02; CI:1.01-1.03, p &lt; 0.001 were associated with poor OS, whereas OS was not dependent on the sex, race, grade, insurance status, surgery, and chemotherapy. Conclusions: This is the largest registry-based study on PSCC to date. PSCC had a diverse OS varied significantly according to increasing age and stage of the disease at presentation. Surgical resection of primary tumor was associated with improved OS in stages I-II, whereas chemotherapy improved OS in stage IV disease. The results of our study may aid the prognostication of patients and in treatment decision making.
US Emergency Department Encounters for Firearm Injuries According to Presentation at Trauma vs Nontrauma Centers
Authors: Edouard Coupet, Yanlan Huang, M. Kit Delgado
Journal: JAMA Surgery (2019)

This study uses the 2009-2014 Nationwide Emergency Department Sample to describe the volume and disposition of individuals with firearm injuries presenting to US emergency departments to determine opportunities to deliver interventions to prevent recurrent injury.
Generation and molecular recognition of melanoma-associated antigen-specific human gamma delta T cells.
Authors: P.M. Benveniste, S. Roy, M. Nakatsugawa, E.L.Y. Chen, L. Nguyen, D.G. Millar, P.S. Ohashi, N. Hirano, E.J. Adams, J.C. Zuniga-Pflucker
Journal: Science Immunology (2019)
LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation
Authors: Chongbiao Huang, Yang Li, Zengxun Li, Yang Xu, Na Li, Yi Ge, Jie Dong, Antao Chang, Tiansuo Zhao, Xiuchao Wang, Hongwei Wang, Shengyu Yang, Keping Xie, Jihui Hao, He Ren
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Oxygen and glucose deprivation is a common feature of the solid tumor. Regulatory network underlying the adaptation of cancer cells to the harsh microenvironment remains unclear. We determined the mechanistic role of LIM and senescent cell antigen-like–containing domain protein 1 (LIMS1) in cancer cell survival under oxygen–glucose deprivation conditions. Experimental Design: The expression level of LIMS1 was determined by IHC staining and analyzing the mRNA expression profiles from The Cancer Genome Atlas of three human solid tumors. Roles of LIMS1 in cancer cell metabolism and growth were determined by molecular and cell biology methods. A jetPEI nanocarrier was used as the vehicle for anti-LIMS1 siRNAs in mouse models of cancer therapeutics. Results: LIMS1 expression was drastically elevated in pancreatic ductal adenocarcinoma (PDAC). High LIMS1 level was associated with advanced TNM stage and poor prognosis of patients with tumor. Increased LIMS1 expression was pivotal for tumor cells to survive in the oxygen–glucose deprivation conditions. Mechanistically, LIMS1 enhanced GLUT1 expression and membrane translocation, which facilitated tumor cell adaptation to the glucose deprivation stress. Furthermore, LIMS1 promoted HIF1A protein translation by activating AKT/mTOR signaling, while hypoxia-inducible factor 1 (HIF1) transactivated LIMS1 transcription, thus forming a positive feedback loop in PDAC cell adaptation to oxygen deprivation stress. Inhibition of LIMS1 with jetPEI nanocarrier–delivered anti-LIMS1 siRNAs significantly increased cell death and suppressed tumor growth. Conclusions: LIMS1 promotes pancreatic cancer cell survival under oxygen–glucose deprivation conditions by activating AKT/mTOR signaling and enhancing HIF1A protein translation. LIMS1 is crucial for tumor adaptation to oxygen–glucose deprivation conditions and is a promising therapeutic target for cancer treatment.
Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes
Authors: Gillen Oarbeascoa, Sara Redondo, Maria Jose Morán-Jiménez, Amalia Domingo, Cristina Muñoz-Linares, Maria Isabel Moreno-Carralero, Jose Maria Bellon, Juan Francisco del Campo Rincon, Jose Luis Díez-Martín, Patricia Font
Journal: Blood (2018)
Abstract P6-18-01: Treatment benefit of ribociclib + letrozole in patients with <i>de novo</i> disease and visceral metastases from the MONALEESA-2 study
Authors: JA O'Shaughnessy, CL Arteaga, LL Hart, DL Lindquist, JT Beck, DD Purkayastha, N Caria, GN Hortobagyi
Journal: Cancer Research (2019)

Abstract Background: Ribociclib (ribo) + letrozole (LET) demonstrated efficacy and safety in first-line treatment of patients (pts) with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC). Most endocrine therapy (ET)–naive pts with de novo ABC respond to ET, but first-line monotherapy with ET or fulvestrant elicited only moderate efficacy in the FALCON study of pts with visceral metastases (mets). Visceral mets are associated with poor prognosis and may warrant novel treatment options in addition to ET. Here, we present clinical outcomes of treatment with ribo in pts with de novo ABC and visceral mets. Methods: In the MONALEESA-2 study, postmenopausal women with HR+, HER2− ABC (N=668) were randomized (1:1) to receive either ribo 600 mg/d or placebo (3 wk on/1 wk off) + LET 2.5 mg/d (continuous). The primary endpoint was median progression-free survival (mPFS). Results: All pts in this analysis (n=227) had de novo ABC; 108 pts had visceral mets (ribo, n=53; placebo, n=55). Baseline characteristics were similar between the ribo and placebo groups. The median follow-up time was 26.4 months. In pts with visceral mets, mPFS was significantly higher in the ribo group (30.3 months) than in the placebo group (14.1 months; hazard ratio, 0.52; 95% CI, 0.295–0.905; P=0.019). Rates of PFS in these pts in the ribo vs placebo group, respectively, were 76% vs 60% at 12 months and 60% vs 36% at 24 months. Among the pts with visceral mets, clinical benefit rate (CBR) was 79% vs 71% in the ribo vs placebo group, and overall response rate (ORR) in pts with measurable disease at baseline was 55% vs 46%, respectively. In pts without visceral mets (ribo, n=61; placebo, n=58), PFS rates in the ribo vs placebo group, respectively, were 87% vs 72% at 12 months and 66% vs 51% at 24 months. Safety results were consistent with the overall population, and responses were durable with ribo + LET irrespective of whether the pts had visceral or nonvisceral mets. Conclusions: Clinical outcomes from this analysis of the MONALEESA-2 study are consistent with those of the overall population, and ribo + LET prolonged the mPFS and improved ORR and CBR in pts with de novo ABC with visceral mets vs placebo + LET. Citation Format: O'Shaughnessy JA, Arteaga CL, Hart LL, Lindquist DL, Beck JT, Purkayastha DD, Caria N, Hortobagyi GN. Treatment benefit of ribociclib + letrozole in patients with de novo disease and visceral metastases from the MONALEESA-2 study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-01.
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors
Authors: Nisha Pillay, Anthony Tighe, Louisa Nelson, Samantha Littler, Camilla Coulson-Gilmer, Nourdine Bah, Anya Golder, Bjorn Bakker, Diana C.J. Spierings, Dominic I. James, Kate M. Smith, Allan M. Jordan, Robert D. Morgan, Donald J. Ogilvie, Floris Foijer, Dean A. Jackson, Stephen S. Taylor
Journal: Cancer Cell (2019)

Inhibitors of poly(ADP-ribose) polymerase (PARP) have demonstrated efficacy in women with BRCA-mutant ovarian cancer. However, only 15%–20% of ovarian cancers harbor BRCA mutations, therefore additional therapies are required. Here, we show that a subset of ovarian cancer cell lines and ex vivo models derived from patient biopsies are sensitive to a poly(ADP-ribose) glycohydrolase (PARG) inhibitor. Sensitivity is due to underlying DNA replication vulnerabilities that cause persistent fork stalling and replication catastrophe. PARG inhibition is synthetic lethal with inhibition of DNA replication factors, allowing additional models to be sensitized by CHK1 inhibitors. Because PARG and PARP inhibitor sensitivity are mutually exclusive, our observations demonstrate that PARG inhibitors have therapeutic potential to complement PARP inhibitor strategies in the treatment of ovarian cancer.
Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy
Authors: Robert Frank Cornell, Samuel Z. Goldhaber, Brian G Engelhardt, Javid Moslehi, Madan Jagasia, Daryl Patton, Shelton Lacy Harrell, Robert L Hall, Houston Wyatt, Gregory Piazza
Journal: Blood (2018)
Phenotypes of Diamond Blackfan Anemia Patients with RPL35A Haploinsufficiency Due to 3q29 Deletion Compared with RPL35A Single Nucleotide Variants or Small Insertion/Deletions
Authors: Neelam Giri, Matthew Gianferante, Evangelia Atsidaftos, Marcin W. Wlodarski, Paola Quarello, Jana Volejnikova, Polyxeni Delaporta, Vijay G. Sankaran, Jason E. Farrar, Maryam Hussain, Lisa J. McReynolds, Antonis Kattamis, Jeffrey M Lipton, Charlotte Niemeyer, Dagmar Pospisilova, Ugo Ramenghi, Sharon A. Savage, Adrianna Vlachos, Blanche P. Alter
Journal: Blood (2018)
A nationwide multicenter study in patients with unresectable hepatocellular carcinoma treated with lenvatinib in real world practice in Japan.
Authors: Kaoru Tsuchiya, Masayuki Kurosaki, Shun Kaneko, Toru Kimura, Hiroyuki Marusawa, Hirotaka Arai, Takehiko Abe, Hiroyuki Kimura, Keiji Tsuji, Koichiro Furuta, Chikara Ogawa, Ryoichi Narita, Yuji Kojima, Takehiro Akahane, Yasushi Uchida, Hideo Yoshida, Haruhiko Kobashi, Atsunori Kusakabe, Kouji Joko, Namiki Izumi
Journal: Journal of Clinical Oncology (2019)

364 Background: Lenvatinib(LEN) has been approved as a single agent for patients with unresectable hepatocellular carcinoma (u-HCC) since Mar 2018 in Japan. A few results from a large sample size cohort of LEN therapy in real world practice has been reported. Therefore, we performed a retrospective nationwide multicenter study. Methods: A total of 116 u-HCC patients received LEN from March 2018 at 14 sites in Japan were registered. Tumour assessments in accordance with RECICT ver1.1 and modified RECIST were done using dynamic CT or MRI within 4-8 weeks and every 6-8 weeks thereafter. Adverse events (AEs) were graded according to the CTCAE ver4.0. Results: Median age was 72 (46-91)years, 88 (75.9%) patients were male, and median body weight was 60 (30-94) kg. The baseline liver function was Child-Pugh class A in 106 (91.4%) patients. Seventy-three (62.9%) patients were BCLC stage C. As the 2nd-line therapy (after sorafenib), 28 (24.1%) patients received LEN and 17 (14.7%) patients did as the 3rd-line (after regorafenib). Median observation time was 2.5 months and one patient died from HCC progression. The imaging findings of 49 (42.2%) patients were evaluated at 4-8weeks. Based on mRECIST, CR was shown in 3 (6.1%), PR in 14 (28.6%), SD in 23 (46.9%), and PD in 6 (12.2%). In the 3 patients, target lesions of liver showed PR, however bone metastases had progressed. [overall response rate (ORR) 34.7%, disease control rate (DCR) 81.6%]. ORR and DCR of tyrosine kinase inhibitor (TKI) naïve patients (n = 26) were 34.6% and 80.8%, while those of TKI experienced (n = 23) were 34.8% and 82.6%. The most common any-grade AEs were hypertension (52.0%), diarrhoea (32.1%), decreased appetite (63.5%) and fatigue (49.4%). Hand-food skin reaction (HFSR) was observed in 28% of patients. Conclusions: The efficacy of LEN therapy in real world practice in Japan was similar to the phase 3 clinical trial, even though elderly patients with lower body weight were included in this study. The incidence of HFSR during LEN in real world practice was lower than that of the sorafenib group in the phase 3 trial of LEN. Decrease appetite and fatigue must be carefully monitored and managed during LEN therapy.
Abstract 16142: Aortic Flow Eccentricity and Wall Shear Stress in the Dilated Ascending Aorta With and Without Aortic Valve Stenosis and Regurgitation
Authors: Kenichiro Suwa, Ozair A Rahman, Emilie Bollache, Michael J Rose, Amir A Rahsepar, Hideharu Hayashi, James Carr, Jeremy D Collins, Alex J Barker, Michael Markl
Journal: Circulation (2016)

Introduction: Ascending aortic (AAo) dilatation is associated with aortic valve stenosis (AS) and regurgitation (AR) but can also be present in patient with normal aortic valves. The understanding ...
The integrity of the cholecystokinin receptor gene in gallbladder disease and obesity*1
Authors: G NARDONE
Journal: Hepatology (1995)

Cholesterol gallstone disease and obesity are common and often associated disorders that could be affected by dysfunction of the receptor for cholecystokinin (CCK). Extending earlier studies that identified a defect at the level of receptor-G protein coupling in cholesterol gallstone disease, we characterized the primary structure of the gallbladder CCK receptor in patients undergoing a cholecystectomy. Represented were patients with cholesterol gallstones, as well as controls with pigment gallstones or without gallbladder disease. Both groups were composed of the range of body habitus from lean to morbidly obese. No evidence of any sequence mutation or polymorphism in the CCK receptor gene was found in any patient. This should lead future investigations of the pathogenesis of these problems toward the possible contribution of the plasmalemmal environment in affecting the association between normal receptors and G proteins.
Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression
Authors: Nicholas Borcherding, Andrew P. Voigt, Vincent Liu, Brian K. Link, Weizhou Zhang, Ali Jabbari
Journal: Clinical Cancer Research (2019)

Cutaneous T-cell lymphomas (CTCL), encompassing a spectrum of T-cell lymphoproliferative disorders involving the skin, have collectively increased in incidence over the last 40 years. Sézary syndrome is an aggressive form of CTCL characterized by significant presence of malignant cells in both the blood and skin. The guarded prognosis for Sézary syndrome reflects a lack of reliably effective therapy, due, in part, to an incomplete understanding of disease pathogenesis.
Hepatoblastoma Mimicking Hemangioma in Labeled Red Blood Cell Scintigraphy
Authors: Ayça Arçay, Gülen Tüysüz Kintrup, Mustafa Tekinalp Gelen, Gökhan Arslan, Binnur Karayalçin
Journal: Clinical Nuclear Medicine (2019)

Abstract Although 99m Tc red blood cell (RBC) scintigraphy is a very specific method to differentiate a hemangioma from other hepatic masses, several cases of false-positive 99m Tc RBC scintigraphy have been previously reported throughout the literature. We report an additional case that presented in a 15-month-old boy with hepatoblastoma showing increased labeled RBC activity mimicking hemangioma.
Abstract 20894: Therapeutic Efficacy of the Exosomes Derived From Human Induced Pluripotent Stem Cells (iPSCs) vs. Human Induced Pluripotent Stem Cells-Derived Cardiomyocytes (iCMs) in Murine Myocardial Injury Model
Authors: Xuebin Fu, Hiromi Sano, Daniel von Bornstaedt, Joseph Woo, Phillip Yang
Journal: Circulation (2017)

Introduction: In murine myocardial injury model, the favorable effects of iCMs transplantation are not completely understood. Exosomes secreted from transplanted cells may mediate beneficial effect...
Advances in the Gene Therapy of Patients with Fanconi Anemia
Authors: Juan A. Bueren, Susana Navarro, Wei Wang, Rebeca Sanchez-Dominguez, Eva Merino, Jose C Segovia, Anne Galy, María L. Lamana, Rosa M Yañez, Jose A Casado, Yari A. Gimenez, Francisco J Roman-Rodriguez, Lara A. Alvarez, Roser Pujol, Jordi Surralles, Ricardo López, Nagore García de Andoín, Albert Catala, Eva Galvez, Raquel Hladun, Jonathan D Schwartz, Manfred Schmidt, Cristina Díaz de Heredia, Paula Rio, Julian Sevilla
Journal: Blood (2018)
Pre-Conditioning Serum Leptin Levels Predict Early Relapse Rates of High Risk AML after Allogeneic Stem Cell Transplantation
Authors: Mark-Alexander Schwarzbich, Hao Dai, Lambros Kordelas, Dietrich W. Beelen, Aleksandar Radujkovic, Carsten Müller-Tidow, Peter Dreger, Thomas Luft
Journal: Blood (2018)
Differences in overall survival for patients with cholangiocarcinoma: Racial/ethnic disparity or socioeconomic factors?
Authors: Rachel M Lee, Yuan Liu, Mohammad Yahya Zaidi, Adriana Carolina Gamboa, Maria C. Russell, Kenneth Cardona, Shishir K. Maithel
Journal: Journal of Clinical Oncology (2019)

380 Background: Inequities in cancer survival are well documented. Whether disparities in overall survival (OS) result from inherent racial differences in underlying disease biology or socioeconomic factors (SEF) is not known. Our aim was to define the association of race/ethnicity and SEF with OS in pts with cholangiocarcinoma (CCA). Methods: Pts with CCA of all sites and stages in the National Cancer Data Base (2004-14) were included. Racial/ethnic groups were defined as non-Hispanic White (NH-W), non-Hispanic Black (NH-B), Asian, and Hispanic. Income and education were based on census data for pts’ zip code. Income was defined as high (³$63,000) vs low ( &lt; $63,000). Primary outcome was OS. Results: 27,151 pts were included with a mean age of 68 yrs; 51% were male. 78% were NH-W, 8% NH-B, 6% Asian, and 6% Hispanic. 56% had Medicare, 33% private insurance, 7% Medicaid, and 4% were uninsured. 67% had high income. 21% lived in an area where &gt; 20% of adults did not finish high school. NH-B and Hispanic pts had more unfavorable SEF including uninsured status, low income, and less formal education than NH-W and Asian pts (all p &lt; 0.001). They were also younger, more likely to be female and to have metastatic disease (all p &lt; 0.001). Despite this, NH-B race and Hispanic ethnicity were not associated with decreased OS. Male sex, older age, non-private insurance, low income, lower education, non-academic facility, location outside the Northeast, higher Charlson-Deyo score, worse grade, larger tumor size, and higher stage were all associated with decreased OS (all p &lt; 0.001). On MV analysis, along with adverse pathologic factors, type of insurance (p = 0.003), low income (p &lt; 0.001), and facility type and location of treatment (p &lt; 0.001) remained associated with decreased OS; non-white race/ethnicity was not. Conclusions: Disparities in survival exist in CCA, however they are not driven by race/ethnicity. Non-privately insured and low-income pts had decreased OS, as did pts treated at non-academic centers and outside the Northeast. This suggests that decreased ability to access and afford care results in worse outcomes, rather than biological differences amongst racial/ethnic groups.
A Study to Predict Response to Azacitidine or Lenalidomide/Azacitidine Combination Therapy in MDS and AML Patients Using a Computational Biological Modeling (CBM) Approach
Authors: Ravi Vij, Mark A. Fiala, Mathew A. Cherian, Neeraj Kumar Singh, Diwyanshu Sahu, Ilu Kumari, Ankitha Narayan, Poornachandra G, Shireen Vali, Taher Abbasi
Journal: Blood (2017)